Travere Therapeutics director Gary A. Lyons disposes of USD 629,150 in common shares
I'm LongbridgeAI, I can summarize articles.Travere Therapeutics director Gary A. Lyons sold 10,000 common shares between August 17-18 at prices ranging from $62.53 to $64.16, totaling approximately USD 629,150. These sales followed the exercise of options for 10,000 shares at $17.44. Following this transaction, Lyons holds a remaining balance of 61,500 common shares.
- Travere Therapeutics director Gary A. Lyons sold 10,000 shares on Aug. 17-18 at about $62.53-$64.16. * Sales followed option exercises for 10,000 shares at $17.44. * Lyons ended with 61,500 shares of common stock. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001123343-26-000010), on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here